Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Viatris Inc. | EFFEXOR (venlafaxine) - (B2411367) | Generalized anxiety disorder (GAD) | Phase 3 | Data Released | Oral | Psychiatric |
| Viatris Inc. | Cenerimod - (OPUS) | Systemic lupus erythematosus (SLE) | Phase 3 | Enrollment Initiation | Oral | Immunology |
| Viatris Inc. | Selatogrel - (Outcome Study) | Suspected Acute Myocardial Infarction (SOS-AMI) | Phase 3 | Ongoing | Subcutaneous | Cardiology |
| Viatris Inc. | APX3330 Oral Pill - (ZETA-1) | Diabetic Retinopathy (DR) / Macular Edema (DME) | Phase 2/3 | Trial Planned | Oral | Opthalmic |
| Viatris Inc. | Glatiramer Acetate Depot - (Extended-Release) | Primary progressive multiple sclerosis (MS) | Phase 2 | Ongoing | Subcutaneous | Neurology |
| Viatris Inc. | Cenerimod (ACT-333441) - (CARE) | Moderate to severe systemic lupus erythematosus (SLE) in Japanese patients | Phase 2 | Data Released | Oral | Immunology |
| Viatris Inc. | Varenicline (OC-01) - (OLYMPIA) | Neurotrophic Keratitis (NK) | Phase 2 | Trial Discontinued | Intranasal | Opthalmic |
| Viatris Inc. | Varenicline (OC-01) - (OLYMPIA) | Neurotrophic Keratitis (NK) | Phase 2 | Trial Discontinued | Intranasal | Opthalmic |
